Last reviewed · How we verify

SCTB14 — Competitive Intelligence Brief

SCTB14 (SCTB14) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47/SIRPα axis inhibitor. Area: Oncology.

phase 3 CD47/SIRPα axis inhibitor CD47/SIRPα axis Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SCTB14 (SCTB14) — Sinocelltech Ltd.. SCTB14 is a small molecule targeting the CD47/SIRPα axis.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SCTB14 TARGET SCTB14 Sinocelltech Ltd. phase 3 CD47/SIRPα axis inhibitor CD47/SIRPα axis
KI1106 4g, QD KI1106 4g, QD Kuhnil Pharmaceutical Co., Ltd. phase 3 CD47/SIRPα inhibitor CD47/SIRPα axis
SHR-1314 SHR-1314 Jiangsu HengRui Medicine Co., Ltd. phase 3 CD47/SIRPα inhibitor CD47/SIRPα axis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47/SIRPα axis inhibitor class)

  1. Akeso · 1 drug in this class
  2. AltruBio Inc. · 1 drug in this class
  3. Bristol-Myers Squibb · 1 drug in this class
  4. City of Hope Medical Center · 1 drug in this class
  5. Cloudbreak Therapeutics, LLC · 1 drug in this class
  6. Sinocelltech Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SCTB14 — Competitive Intelligence Brief. https://druglandscape.com/ci/sctb14. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: